Copenhagen 2016 Registration Programme Exhibitor Information Virtual Exhibition Satellite Meetings Glaucoma Day 2016 Hotel Star Alliance

10 - 14 Sept. 2016, Bella Center, Copenhagen, Denmark

This Meeting has been awarded 27 CME credits


escrs app advert yo advert


Search Title by author or title

The prevention of macular edema in non-proliferative diabetic retinopathy patients after cataract surgery

Poster Details

First Author: A. Fursova RUSSIAN FEDERATION

Co Author(s):    M. Tarasov   G. Pustovaya                 

Abstract Details


To study the efficacy of intravitreal ranibizumab in patients with non-proliferative diabetic retinopathy (NPDR) in the prevention of macular edema (ME) development after cataract surgery.


cataract surgery in patients with diabetic retinopathy


126 patients (126 eyes) (mean age 65.7 yrs, 95 females, 71 males) with NPDR with cataract and without signs of ME were included to the study. All patients underwent cataract phacoemulsification with aspherical hydrophobic intraocular lens implantation; the surgery did not have complications. 86 patients received the injection of ranibizumab 0.5 mg intravitreally in the end of the cataract surgery. Other patients (control group) did not receive ranibizumab. Follow-up was 120 days after the surgery. Diabetic ME rate and central macular thickness (CMT) were assessed at 15, 30, 60, 90 and 120 days.


Patients from the study and control group were comparable (p>0.05) at age (66.9 vs 64.5 yrs), male:female ratio (1:1.32 vs 1:1.27), diabetes duration (11.8±6.4 vs 12.3±6.5) and baseline CMT (198±39.2 μm vs 202.1±7.2 μm). The incidence of ME in the study group was 3.5%, 4.7%, 5.8%, 5.8% and 5.8% at 15, 30, 60, 90 and 120 days. DME rate was significantly higher in patients who did not receive ranibizumab: 26.3%, 36.3%, 40%, 40% and 41.3%. Final CMT was numerically higher in control group – 379±5.2 μm vs 322±7.4 μm.


The incidence of DME in patients with NPDR after cataract surgery and ranibizumab injections was significantly lower – 5.8% at final visit compared to control group (41.3%, p<0.05).

Financial Disclosure:


Back to Poster listing